


# Vegvisir Technologies

## Accelerating Oral Delivery of Therapeutic Peptides


### Problem - Low oral peptide delivery

Oral peptide delivery is inefficient mainly due to low epithelial transport





### Our solution

Tailored heteropolymers forming coacervates with peptides




- Polymer tailored to each peptide
- Protects the peptide in the intestine
- Improves transport across intestinal barrier

### Our Workflow for Optimization



### Mouse study indicating increased oral bioavailability of semaglutide



### Market size

The global peptide therapeutics market exceeds **USD 60B** in 2025 and is rapidly growing at around **10% CAGR**.

### Business Opportunity

We are seeking for **partner companies in Pharma and biotech**, and **future investors** interested in **delivery platform technologies**.

### Intellectual Property Rights


PCT application submitted.

To be published in August 2026.


### Our Team



**CEO**  
PhD. Philip M. Lund  
Technical University of Denmark



**CSO**  
Prof. Anton A. A. Autzen  
Technical University of Denmark



**CBO**  
MBA, MPharm. Mads H. Sørensen  
Technical University of Denmark



**Contact information**  
Philip Mark Lund  
CEO  
+45 22 83 41 82  
pmlu@dtu.dk

